Gilead (GILD) says bictegravir & lenacapavir single-tablet regimen maintained virological suppression in people with HIV
Importance
Level 1
- BIC/LEN was generally well tolerated, with no significant or new safety concerns identified
#GILEAD SCIENCES INC#GILD.US#EQUITIES#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#GILD#GLOBAL NEWS